PHAT
Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. (PHAT) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 49.3, with 0/3 trend checks passing.
PHAT with MA50 and MA200
Key levels & signals
Phathom Pharmaceuticals, Inc. (PHAT) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $11.05, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 0.6% and below the 200-day moving average by 13.0%.
PHAT currently has an RSI reading of 49.3, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing PHAT next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
Learn the indicators behind this page
More stock opportunities
Common questions about PHAT
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.